CHRS at a glance
Coherus Oncology, Inc. (CHRS, SEC CIK 1512762) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 28, 2026 and Form 4 insider filings as recently as June 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Coherus Oncology, Inc. (CHRS) reported revenue of $42.2 million (down 84.2% from FY2024) and net income of $168.0 million. Diluted EPS was $1.43.
- As of June 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Coherus Oncology, Inc. (CHRS) shares worth $40.3 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $42.2M
- −84.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 22 funds
- $40.3M · +0 vs prior quarter
- Latest 8-K
- Aug 28, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $14.3M, up $4.1M YoY from $10.3M, driven by LOQTORZI volume growth
- LOQTORZI revenue $13.6M, up $3.7M YoY from $10.0M
- Gross margin 70% vs 67% YoY, with cost of goods sold $4.2M vs $3.4M
- Cash, equivalents and marketable securities $105.3M vs $172.1M at December 31, 2025
- 2026 outlook: higher net revenue, lower R&D and SG&A expenses, comparable interest expense
Risk Factors
- UDENYCA Sale completed, increasing profitability risk as LOQTORZI replaces the divested product’s larger revenue contribution
- Cash, cash equivalents and marketable securities $105.3 million as of June 30, 2026, with continued dependence on additional funding
- LOQTORZI competition from chemotherapy and off-label immunotherapy agents in nasopharyngeal carcinoma
- Regulatory noncompliance exposure, including potential product recalls, approval withdrawal, civil or criminal penalties
- LOQTORZI license obligations include up to $90.0 million in regulatory milestones and $290.0 million in sales-threshold payments
AI summary of the CHRS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- At-the-market equity facility enabling up to $50.0 million in common-stock sales
- No obligation to issue shares, preserving financing flexibility but creating potential dilution
Item 1.02: Termination of a Material Definitive Agreement
- Prior Loan Agreement fully repaid and terminated on August 14, 2026
- All related security interests released, removing lender claims against pledged assets
Item 1.01: Entry into a Material Definitive Agreement
- $55M senior secured term loan funded August 14, 2026, maturing August 2031
- Refinanced prior debt maturing May 2029, replacing 8.0% plus three-month SOFR interest
Item 7.01: Regulation FD Disclosure
- Special dividend of contingent value rights declared by Coherus Oncology’s board
- CVR terms and shareholder FAQ available through the company’s website
Item 8.01: Other Events
- One CVR per common share held at 5:00 p.m. ET on September 30, 2026
- Payments depend on net cash proceeds from Legacy BioSim Asset monetization during October 7, 2026–October 7, 2028
AI summaries of CHRS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CHRS
Don't miss the next CHRS filing
- Alerts as it files. A push when CHRS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CHRS, by share count.
- Ask anything. An AI agent that reads every CHRS filing and answers with sources.
CHRS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Newcomer Lee Nisley | A | Jun 5, 2026 | 60,000 | - |
| Karachun Rita A | A | Jun 5, 2026 | 60,000 | - |
| Wahlstrom Mats | A | Jun 5, 2026 | 30,000 | - |
| Wahlstrom Mats | A | Jun 5, 2026 | 60,000 | - |
| Ryan Michael Lee | A | Jun 5, 2026 | 60,000 | - |
| O'Donnell-Tormey Jill | A | Jun 5, 2026 | 60,000 | - |
| Newton Charles W. | A | Jun 5, 2026 | 60,000 | - |
| O'Donnell-Tormey Jill | A | Jun 5, 2026 | 30,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $267.0M | $42.2M |
| Operating Income | -$203.2M | -$111.7M | -$181.1M |
| Net Income | -$237.9M | $28.5M | $168.0M |
| Op. Margin | - | -41.8% | -429.5% |
| Net Margin | - | 10.7% | 398.4% |
| Balance Sheet | |||
| Total Assets | $629.6M | $448.5M | $258.3M |
| Equity | -$193.4M | -$132.0M | $61.0M |
| ROE | 123.0% | -21.6% | 275.4% |
| Per Share | |||
| EPS | $-2.53 | $0.25 | $1.43 |
| Cash Flow | |||
| Operating CF | - | -$20.4M | -$138.5M |
| CapEx | $286K | - | - |
Source: XBRL data in Coherus Oncology, Inc. (CHRS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CHRS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 22 | $40.3M |
| Q1 2026 | 22 | $44.2M |
| Q4 2025 | 20 | $39.4M |
| Q3 2025 | 19 | $44.8M |
| Q2 2025 | 20 | $21.7M |
| Q1 2025 | 17 | $16.4M |
| Q4 2024 | 13 | $24.3M |
| Q3 2024 | 13 | $10.2M |
- BlackRock+1.64M (+16%)
- Vanguard Capital Management LLC+496.7K (+9%)
- Vanguard Portfolio Management LLC+278.9K (+46%)
- Renaissance Technologies LLC+231.4K (+70%)
- Northern Trust+215.7K (+24%)
- Millennium Management−291.2K (-93%)
- Citadel Advisors LLC−191.8K (-82%)
- Goldman Sachs Group−94.1K (-14%)
- Two Sigma Investments−42.6K (-2%)
- Bank of America Corp−21.6K (-7%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 146 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CHRS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 28, 2026 | - | Analysis | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 27, 2026 | - | - | |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-K | Mar 9, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 8-K | Feb 17, 2026 | - | - | |
| SC 13G | Feb 5, 2026 | - | - | |
| 8-K | Feb 4, 2026 | - | - | |
| 4 | Jan 26, 2026 | - | - | |
| 4 | Jan 26, 2026 | - | - | |
| 8-K | Jan 23, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
CHRS SEC filings: frequently asked questions
Which institutions hold CHRS stock?
As of June 30, 2026, the largest Coherus Oncology, Inc. (CHRS) holders among the 13F filers tracked by SignalX were BlackRock ($16.8 million), Vanguard Capital Management LLC ($8.3 million), State Street Corp ($3.3 million), Two Sigma Investments ($3.2 million), AQR Capital Management ($1.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CHRS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Coherus Oncology, Inc. (CHRS) reported revenue of $42.2 million (down 84.2% from FY2024) and net income of $168.0 million. Diluted EPS was $1.43. The figures come from the XBRL data in the 10-K.
What did CHRS report in its latest 8-K?
Coherus Oncology, Inc. (CHRS) filed an 8-K on August 28, 2026 reporting Item 8.01 (Other Events). At-the-market equity facility enabling up to $50.0 million in common-stock sales.
What are the latest CHRS SEC filings?
Coherus Oncology, Inc. (CHRS) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 28, 2026 and a Form 4 insider filing on June 9, 2026.
What is CHRS's SEC CIK number?
Coherus Oncology, Inc. (CHRS)'s SEC Central Index Key (CIK) is 1512762. EDGAR lists every CHRS filing under that number.
Ask anything about CHRS
The research agent reads CHRS's filings, financials, insider trades and 13F holders, then answers with sources.